FSH - an Aging Hormone?

节目概要 肥胖症和骨质疏松症是普遍影响老年人的全球公共卫生危害， 通常在绝经后妇女中共存。虽然有一个有限的医疗设备， 尽管目前已批准用于治疗骨质疏松症的五种药物疗效不佳，且副作用不可接受，但这些药物仍受到限制。 因此，治疗这两种慢性衰老疾病的新方法需要合作和严格的 独立但完全互动的实验室之间的综合方案。这个U19建立在一个公司的基础上 严格和透明的研究基础，来自Mone博士之间的长期合作 Zaidi和Clifford罗森，其结果于去年发表（Nature，2017，PMID：28538730）。我们 将FSH确定为预防肥胖和骨质疏松症的独特靶点。我们用多克隆抗体 Fshβ通过阻断其与Fsh受体（Fshr）的接触，预防高脂饮食诱导的肥胖， 卵巢切除导致的骨质疏松症另外，我们的FSH抗体引发了能量的出现- 在白色脂肪组织中产生“米色”脂肪细胞。基于这些研究和其他研究，我们现在假设 FSH也可能是一种重要的衰老激素。因此，我们建议进行一次全面的， 阻断FSH信号传导的影响的多管齐下和跨学科的研究， 我们的单克隆抗FSH抗体或Fshr-/-小鼠的基因，对寿命，脂肪增加，骨髓肥胖， 和小鼠骨骼健康。我们还将使用ThermoMice研究FSH对脂肪细胞的作用机制 报告了“beiging”，测量从头脂肪生成的AdipoChaser小鼠，以及最先进的技术 用于转录组脂质组和生物能量分析为了支持我们的临床前观察， 为了在人群中测试我们的单克隆抗体，我们建议对老年女性和男性进行流行病学研究。 在雷克雅未克老年人队列中。我们将研究血清FSH是否可以作为一个替代指标， 骨质流失、内脏脂肪增加、骨髓肥胖，最终导致骨折风险。提供必要 四个研究中心的资源--缅因州西奈山伊坎医学院医学中心 研究所，得克萨斯大学西南医学中心和加州大学旧金山分校 Francisco-我们提出了三个总体多功能核心：Skeleton和代谢表型核心， 抗体生产和测试核心，以及行政和生物统计支持核心。总之，我们的U19 这项提案应该使我们能够在理解两种普遍的衰老障碍方面取得新的进展， 此外，还为越来越多的老年人开辟了新的治疗干预途径。

PROGRAM SUMMARY Obesity and osteoporosis are global public health hazards that commonly affect older individuals and often co-exist in postmenopausal women. While a restricted armamentarium of therapies is available for osteoporosis, the five approved agents for obesity are limited by poor efficacy and unacceptable side effects. Hence, new approaches to treat these two chronic conditions of aging require a collaborative and rigorous integrative program between independent, but fully interactive laboratories. This U19 builds on a firm foundation of rigorous and transparent research, born from a longstanding collaboration between Drs. Mone Zaidi and Clifford Rosen, the results of which were published last year (Nature, 2017, PMID: 28538730). We identified FSH as a unique target to prevent both obesity and osteoporosis. We raised a polyclonal antibody to Fshβ, which, by blocking its access to the Fsh receptor (Fshr), prevented high-fat-diet-induced obesity and ovariectomy-induced osteoporosis. In addition, our Fsh antibody triggered the appearance of energy- producing ‘beige’ adipocytes in white adipose tissue. Based on these studies and others, we now postulate that FSH may also be a critical aging hormone. We therefore propose to undertake a comprehensive, multipronged and interdisciplinary study of the effects of blocking Fsh signaling, either pharmacologically using our monoclonal anti-Fsh antibodies or genetically in Fshr-/- mice, on lifespan, fat gain, bone marrow adiposity, and skeletal health in mice. We will also study the mechanism of Fsh action on fat cells using ThermoMice that report ‘beiging,’ AdipoChaser mice that measure de novo adipogenesis, and state-of-the-art technologies for transcriptome, lipidome and bioenergetic profiling. To buttress our preclinical observations and, with a view of testing our monoclonal antibodies in people, we propose an epidemiological study of older women and men in the AGES-Reykjavik Cohort. We will examine whether serum FSH can be used as a surrogate marker for bone loss, visceral fat gain, bone marrow adiposity, and ultimately, fracture risk. To provide necessary resources across the four investigative sites–Icahn School of Medicine at Mount Sinai, Maine Medical Center Research Institute, University of Texas Southwestern Medical Center and the University of California at San Francisco–we propose three overarching multifunctional cores: a Skeletal and Metabolic Phenotyping Core, an Antibody Production and Testing Core, and an Administrative and Biostatistics Support Core. In sum, our U19 proposal should allow us to break new ground in our understanding of two prevalent disorders of aging, in addition to opening new avenues for therapeutic interventions for our increasing numbers of older adults.